![The right viral safety program can guard against costly bioburden incidents in biopharma development](https://www.biopharmadive.com/imgproxy/Hmb1xXTG4Vv8qJaAf61qRMNG1kNSbrzBaduqNhvVNFE/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTIxNTAzNDE2ODcuanBn.webp)
The right viral safety program can guard against costly bioburden incidents in biopharma development
Viral contamination is a threat to biopharmaceutical product development.1 Contaminants can be present in the cells and source materials or introduced during manufacturing, necessitating viral clearance studies for all biological drugs, including vaccines, blood products and cell and gene therapeutics.2 Viral clearance and viral safety are key components of risk mitigation.3 Candace Fox, PhD, virologist…